Sonographic Evaluation of the Single-incision Needleless (Contasure-needleless®) Mini-sling Placement to Predict Success

April 21, 2019 updated by: Murat Yassa, Bartin State Hospital

Transperineal ultrasonography is gaining importance in preoperative and postoperative evaluation of the patient with urinary incontinence with allowing well detailed information about the anterior compartment.

There is little evidence that transperineal sonography can aid surgeons to predict the success or failure after mid-urethral slings.

We aimed to investigate the efficacy of sonography in mini-sling operations to predict the success or failure.

Study Overview

Status

Completed

Detailed Description

Women who are scheduled for anti-incontinence operation due to their stress urinary incontinence will be pre- and postoperatively evaluated by transperineal and introital ultrasound.

Patients will be followed for at least 1 year.

Study Type

Observational

Enrollment (Actual)

64

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bartin, Turkey
        • Bartin State Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

Patients who have stress urinary incontinence and who are scheduled for needleless mini-sling operation.

Description

Inclusion Criteria:

  • Patients with clinically stress urinary incontinence
  • Patients who claim that their condition severely impair their quality of life
  • Patients who are failed on conservative management (life style changes and pelvic floor exercises)

Exclusion Criteria:

  • Patients who have unregulated diabetes mellitus (they will be included after appropriate and sustainable blood glucose regulation)
  • Patients who have neurological condition that may affect the incontinence
  • Patients who have psychiatric disease that may affect the subjective evaluation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
participants
Patients who are scheduled for single-incision needleless (Contasure-needleless®) mini-sling for their stress urinary incontinence. They will be assessed by Pelvic floor ultrasound
Pelvic floor ultrasound will include transperineal and introital ultrasound

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The correlation of failure with the sonographic features of the mesh
Time Frame: Evaluation at postoperative 1st and 4th weeks
Patients will be accepted as failure if their stress test is positive Sonographic features of the mesh includes the shape of the mesh, the distance to the mid-urethra, the position related to the proximal urethra and the angle between the mesh arms on coronal axis
Evaluation at postoperative 1st and 4th weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Nocturia
Time Frame: Evaluation at postoperative 1st and 4th weeks and preoperatively
The nocturia episodes will be evaluated by a "non-validated" Likert scale (between 0-3). Minimum and minimum scores are between 0 and 3. "0" will mean no episode of urinating during the sleep. "1" will mean one episode of nocturia. "2" will mean two episodes of nocturia. "3" will mean three or more episodes of nocturia. Higher values represent worse outcome.
Evaluation at postoperative 1st and 4th weeks and preoperatively
Urge symptoms
Time Frame: Evaluation at postoperative 1st and 4th weeks and preoperatively
Michigan Incontinence Severity Index (M-ISI) scale will be used to assess subjective outcome including urge symptoms. This scale has ten items, consisting of a total M-ISI domain (the sum of items 1-8) and a distinct Bother domain (the sum of items 9 and 10). The total M-ISI score consists of three subdomains (items 1-3 for stress urinary incontinence [SUI], items 4-6 for urge urinary incontinence [UUI], and items 7 and 8 for Pad usage [PU]. The responses for each item range from 0 to 4 on a Likert-type scale, with higher values representing greater symptoms and greater bother. Total domain and subdomain scores are obtained by simply adding the respective answers. The minimally important difference has been determined for the following domains/subdomains: total M-ISI (4 points), SUI (2 points), UUI (2 points), and PU (1 point).
Evaluation at postoperative 1st and 4th weeks and preoperatively
Subjective success
Time Frame: Evaluation at postoperative 1st and 4th weeks
Patient Global Improvement of Improvement will be used to assess the subjective success
Evaluation at postoperative 1st and 4th weeks
POP-Q
Time Frame: Evaluation at postoperative 1st and 4th weeks and preoperatively
POP-Q measurements will be assessed to measure the pelvic floor prolapse if exist
Evaluation at postoperative 1st and 4th weeks and preoperatively
Anterior compartment mobility distances
Time Frame: Evaluation at postoperative 1st and 4th weeks and preoperatively
On maximal Valsalva maneuver: Bladder neck descent (mm), pubourethral distance (mm), urethral thickness (mm, measured at proximal, mid and distal portions) and urethral length (mm)
Evaluation at postoperative 1st and 4th weeks and preoperatively
Anterior compartment mobility angles
Time Frame: Evaluation at postoperative 1st and 4th weeks and preoperatively
On maximal Valsalva maneuver: Proximal urethral rotation (degree), retrovesical angle (degree)
Evaluation at postoperative 1st and 4th weeks and preoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

November 26, 2018

Primary Completion (ACTUAL)

April 21, 2019

Study Completion (ACTUAL)

April 21, 2019

Study Registration Dates

First Submitted

November 24, 2018

First Submitted That Met QC Criteria

December 1, 2018

First Posted (ACTUAL)

December 4, 2018

Study Record Updates

Last Update Posted (ACTUAL)

April 23, 2019

Last Update Submitted That Met QC Criteria

April 21, 2019

Last Verified

April 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Urinary Incontinence,Stress

Clinical Trials on Pelvic floor ultrasound

3
Subscribe